Enzyme (MLN) Price Prediction

Deep Dive

1. Institutional Adoption Momentum (Bullish Impact)

Overview: Enzyme’s November 2025 partnership with CV5 Capital enables tokenized funds spanning crypto, securities, and real-world assets like U.S. Treasuries. This follows its Chainlink CRE integration for automated compliance, targeting institutional DeFi adoption (CV5 Partnership).

What this means: Increased institutional usage could boost MLN’s utility as vaults require fee payments in MLN (burned per transaction). However, price upside depends on whether AUM growth from partnerships outpaces new token minting.

2. Inflation-Deflation Imbalance (Bearish Impact)

Overview: While MLN burns 0.25% of vault AUM as fees, up to 300,600 new tokens are minted annually for development. The protocol’s docs note inflation will likely exceed burns “for years” (Tokenomics).

What this means: Net supply growth could suppress prices unless adoption accelerates dramatically. For context, 300,600 MLN equals ~10% of current circulating supply annually at current minting rates.

3. Liquidity Risks (Mixed Impact)

Overview: MLN lost spot trading pairs on OKX in October 2025, reducing liquidity. However, the CV5 partnership may attract institutional flows that offset retail exit (Delisting).

What this means: Thinner markets heighten volatility – a risk for short-term traders but less critical for long-term holders betting on institutional adoption.

Conclusion

MLN’s trajectory hinges on whether institutional product growth can offset inflationary tokenomics and liquidity erosion. While recent partnerships signal credibility, the token’s 90-day -46.8% decline reflects skepticism about near-term demand catching up to supply.

Key question: Will Q1 2026 vault AUM data show meaningful acceleration from CV5’s tokenized fund launches?